Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status

World J Hepatol. 2024 Mar 27;16(3):353-365. doi: 10.4254/wjh.v16.i3.353.ABSTRACTHepatocellular carcinoma (HCC) is the most common primary tumor of the liver and has a high mortality rate. The Barcelona Clinic Liver Cancer staging system in addition to tumor staging also links the modality of treatment available to a particular stage. The recent description of the tumor microenvironment (TME) in HCC has provided a new concept of immunogenicity within the HCC. Virus-related HCC has been shown to be more immunogenic with higher expression of cytotoxic T lymphocytes and decreased elements for immunosuppression such as regulatory T cells. This immunogenic milieu provides a better response to immunotherapy especially immune checkpoint inhibitors (ICIs). In addition, the recent data on combining locoregional therapies and other strategies may convert the less immunogenic state of the TME towards higher immunogenicity. Therefore, data are emerging on the use of combinations of locoregional therapy and ICIs in unresectable or advanced HCC and has shown better survival outcomes in this difficult population.PMID:38577535 | PMC:PMC10989304 | DOI:10.4254/wjh.v16.i3.353
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research